The changes in retrotransposon-derived enhancer activities may also play a role in endothelial dysfunction of COVID-19 patients via vascular endothelial growth factor A (VEGFA) and endoglin (ENG) gene dysregulation. The gene discussed is ENG; the disease is COVID-19.